Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art

Autor(es)

Di Filippo, Leonardo Delello ^[1] ; Duarte, Jonatas Lobato ^[1] ; Luiz, Marcela Tavares ^[2] ; Cavalcante de Araujo, Jennifer Thayanne ^[1] ; Chorilli, Marlus ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Rodovia Araraquara Jau, Km 01 S-N, BR-14800903 Araraquara, SP - Brazil

^[2] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Sao Paulo - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: Current Neuropharmacology; v. 19, n. 6, p. 787-812, 2021.
• Citações Web of Science: 1

Resumo

Glioblastoma multiforme (GBM) is the most common primary malignant Central Nervous System cancer, responsible for about 4% of all deaths associated with neoplasia, characterized as one of the fatal human cancers. Tumor resection does not possess curative character, thereby radio and/or chemotherapy are often necessary for the treatment of GBM. However, drugs used in GBM chemotherapy present some limitations, such as side effects associated with non-specific drug biodistribution as well as limited bioavailability, which limits their clinical use. To attenuate the systemic toxicity and overcome the poor bioavailability, a very attractive approach is drug encapsulation in drug delivery nanosystems. The main focus of this review is to explore the actual cancer global problem, enunciate barriers to overcome in the pharmacological treatment of GBM, as well as the most updated drug delivery nanosystems for GBM treatment and how they influence biopharmaceutical properties of anti-GBM drugs. The discussion will approach lipid-based and polymeric nanosystems, as well as inorganic nanoparticles, regarding their technical aspects as well as biological effects in GBM treatment. Furthermore, the current state of the art, challenges to overcome and future perspectives in GBM treatment will be discussed. (AU)

• Processo FAPESP: 18/18488-3 - Avaliação do potencial de carreadores lipídicos nanostruturados funcionalizados com bevacizumab para veiculação de docetaxel no tratamento de glioblastoma
• Beneficiário: Leonardo Delello Di Filippo
• Modalidade de apoio: Bolsas no Brasil - Mestrado